Stockscreener 앱 받기
1.325
0.38%
0.005
시간 외 거래:
1.33
0.005
+0.38%
Sonoma Pharmaceuticals Inc 주식(SNOA)의 최신 뉴스
Sonoma Pharmaceuticals Stock Price Forecast. Should You Buy SNOA? - StockInvest.us
Sonoma (SNOA) Market: Holds Near $1.34 in the Available Record; Current Setup: the Session Ends Within the Reported Technical Boundaries on the DayIV Contraction - vinanet.vn
Sonoma (SNOA) Market: Loses 0.75% to Close at $1.33; Key Range: Support at $1.26 and Resistance at $1.40 Frame the Range on the DayMid Cap Momentum - vinanet.vn
Sonoma (SNOA) Shares: Holds Near $1.34 at the Close; Technical View: the Session Ends Within the Reported Technical Boundaries in Latest TradingBear Flag - vinanet.vn
Form 8K Sonoma Pharmaceuticals Inc For: 19 August By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum By Investing.com - Investing.com South Africa
Sonoma Pharmaceuticals Cancels Adjourned Special Stockholder Meeting - TipRanks
Sonoma Pharmaceuticals cancels special meeting due to lack of quorum - Investing.com
Price to earnings forward of Sonoma Pharmaceuticals, Inc. – SWB:O8Z - TradingView
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals reports 60% revenue growth in Q1 - Investing.com
Sonoma FY2027 Q1 earnings: 60% revenue growth moves EBITDA positive - TradingKey
Sonoma Pharmaceuticals Q1 revenue rises on US growth - TradingView
Sonoma Pharmaceuticals Delivers 141% U.S. Revenue Growth in FY Q1, 60% Total Revenue Growth and First-Ever Positive Adjusted EBITDA - Bay to Bay News
BRIEF-Sonoma Pharmaceuticals Q1 Operating Expenses USD 2.6 Million - TradingView
Sonoma U.S. Revenue Climbs 141%; First-Ever Positive Adjusted EBITDA - Stock Titan
Sonoma Pharmaceuticals, Inc. Q1 2027: Revenue $6.41M, EPS $(0.09) — 10-Q Summary - TradingView
Sonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly Revenue - TradingView
Sonoma Pharmaceuticals (SNOA) Slides 5.83% to $1.13 as Key Support Level LoomsStop Loss Guidance - dars.gov.et
SNOA Q1'26 Earnings: EPS estimate is (0.30) USD - TradingView
SNOA Q2 2026 Earnings: Narrow EPS Miss Weighs on SharesROE Trend Analysis - vinanet.vn
Form DEF 14A SONOMA PHARMACEUTICALS For: 29 July By Investing.com - Investing.com Nigeria
Sonoma Pharmaceuticals (SNOA) Hovers Near Support as Slight Decline ContinuesRVOL Breakout - vinanet.vn
Sonoma Pharmaceuticals Inc (SNOA) Institutional Confidence - TradingKey
Sonoma Pharmaceuticals Inc (SNOA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Sonoma Pharmaceuticals Inc - TradingKey
SNOA|Sonoma Pharmaceuticals Inc|Price:1.140|Chg%:-0.020 - TradingKey
Sonoma Pharmaceuticals (SNOA) Slides 1.72% as Stock Holds Above Key Support at $1.08Time Weighted Price - dars.gov.et
TradingKey - TradingKey
SNOA Q2 2026 Earnings: Slight EPS Miss, Stock Edges LowerProfit Warning Alert - vinanet.vn
SNOA Q2 2026 Earnings: EPS Misses Estimates; Stock Rises Amid Operational UpdatesCFO Commentary Report - vinanet.vn
19,898 Common Stock of Sonoma Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 24-JUL-2026. - marketscreener.com
Sonoma Pharmaceuticals (SNOA) Edges Higher as Volume Patterns Suggest Accumulation Near Key SupportAAII Bearish - dars.gov.et
SNOA Q2 2026 Earnings: EPS Misses Estimates by 1.2%; No Revenue Reported, Stock UnchangedManagement Guidance Update - vinanet.vn
Sonoma Pharmaceuticals (SNOA) Holds Steady at $1.26 as Consolidation ContinuesInside Day Breakout - dars.gov.et
Enterprise value to revenue forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Form 4 Sonoma Pharmaceuticals Inc For: 9 July By Investing.com - Investing.com South Africa
Price to sales forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Sonoma Pharmaceuticals (NASDAQ: SNOA) awards CEO 10,000 RSUs in equity grant - Stock Titan
Enterprise value to EBIT forward of Sonoma Pharmaceuticals, Inc. – NASDAQ:SNOA - TradingView
Price to book forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
Price to sales forward of Sonoma Pharmaceuticals, Inc. – FWB:O8Z - TradingView
SNOA Should I Buy - Intellectia AI
Sonoma Pharmaceuticals (SNOA) Secures FDA Clearance for Microdac - GuruFocus
Sonoma Pharmaceuticals receives FDA clearance for wound solution - Investing.com
Sonoma Pharmaceuticals receives FDA clearance for wound solution By Investing.com - Investing.com Canada
Sonoma Pharmaceuticals Receives FDA 510(k) Clearance Expanding Indications and Packaging Options for Microdacyn(R) Wound Irrigation Solution - ACCESS Newswire
Sonoma Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:SNOA) - TradingView
Sonoma Pharmaceuticals Inc (SNOA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
SNOA Q1 2026 Earnings: EPS Misses Estimates by 1.2%, No Revenue Reported, Stock Edges Up 0.87% - po-news-eg.net
Sonoma Pharmaceuticals Expands At-the-Market Equity Offering Capacity - The Globe and Mail
Sonoma Pharmaceuticals Files 8-K for $3.6 Million Common Stock Offering – Nasdaq: SNOA, June 2026 - Minichart
According to a recent filing submitted to the U.S. Securities and Exchange Commission (SEC), Sonoma Pharmaceuticals, Inc. has raised the maximum total offering price of its common stock issuance to $3.64 million. - Bitget
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million - Investing.com UK
Sonoma Pharmaceuticals increases at-the-market offering to $3.64 million By Investing.com - Investing.com Nigeria
1.66%
0.33%
자본화:
|
볼륨(24시간):